Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Takeda Pharmaceuticals USA, Inc, Lexington, MA, USA.
J Hum Hypertens. 2022 Jan;36(1):3-13. doi: 10.1038/s41371-021-00549-w. Epub 2021 May 14.
An important component of hypertension management is the initiation and continuation of antihypertensive medications. Non-adherence during the long-term use of antihypertensive medications is well studied. However, there is a paucity of research about the frequency and clinical consequences of failing to take the first dose of an antihypertensive, a treatment challenge known as initial medication non-adherence (IMN). This systematic literature review summarizes the published evidence from 2010 to 2019 on the prevalence, associated factors, consequences, and solutions for IMN to antihypertensive medications in the United States. Of the fifteen studies identified, nine studies reported the prevalence of IMN, two studies examined patient-reported reasons for IMN, and four studies evaluated interventions aimed to lower IMN. It is estimated that 5-34% of patients do not obtain their new antihypertensive medications. Factors and reasons cited include patient demographics, patient beliefs or perceptions about medications, cost or financial barriers, and clinical characteristics, such as a new hypertension diagnosis or higher co-morbid disease burden. The clinical, economic, and patient-reported outcomes of IMN are not well researched. In addition, interventions to address IMN have yielded inconsistent results. Significant opportunities exist for further research into this dimension of patient behavior to better understand and address IMN to new antihypertensive medications.
高血压管理的一个重要组成部分是启动和继续使用降压药物。长期使用降压药物时不遵医嘱的情况已有大量研究。然而,关于未能服用降压药第一剂的频率和临床后果的研究却很少,这种治疗挑战被称为初始药物不依从(IMN)。本系统文献综述总结了 2010 年至 2019 年在美国发表的关于 IMN 至降压药物的流行率、相关因素、后果和解决方案的证据。在确定的十五项研究中,有九项研究报告了 IMN 的流行率,两项研究检查了患者报告的 IMN 原因,四项研究评估了旨在降低 IMN 的干预措施。据估计,有 5-34%的患者无法获得新的降压药物。提到的因素和原因包括患者人口统计学特征、患者对药物的信念或看法、费用或经济障碍以及临床特征,如新的高血压诊断或更高的合并症负担。IMN 的临床、经济和患者报告的结果尚未得到充分研究。此外,针对 IMN 的干预措施的结果也不一致。进一步研究患者行为的这一方面以更好地了解和解决新的降压药物的 IMN 存在很大的机会。